Биотехнологическая компания Surrozen подала заявку FDA на клинические испытания нового препарата для лечения диабетической макулярной отёчности

Surrozen, Inc. (SRZN) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed for the treatment of diabetic macular edema (DME). SZN-8141 And Mechanism SZN-8141 is designed to combine Frizzled 4 (FZD4)-mediated Wnt agonism with VEGF antagonism in a single molecule. The treatment is intended to address vascular leakage while promoting retinal vascular integrity through complementary mechanisms. Surrozen is developing SZN-8141 for DME and neovascular age-related macular degeneration (wet AMD), two retinal vascular diseases associated with abnormal blood vessel growth and leakage. Preclinical Findings In preclinical studies, SZN-8141 demonstrated greater biological activity in reducing neovascularization and promoting retinal revascularization compared with either Wnt agonist or anti-VEGF monotherapy in a rodent model of retinal vascular disease. SZN-8141 also produced greater reductions in vascular leakage than anti-VEGF therapy in a rodent model of neovascular age-related macular degeneration. Additional preclinical data showed that SZN-8141 stimulated Wnt signaling and promoted normal retinal vessel regrowth while suppressing pathological vessel growth. DUET Phase 1b/2a Study Surrozen plans to evaluate SZN-8141 in the DUET Phase 1b/2a clinical trial in patients with DME. The study is designed to assess the safety and tolerability of SZN-8141, as well as early signs of biological and clinical activity. Surrozen expects to initiate the DUET study by the end of 2026, with initial data anticipated in the second half of 2027. The company is developing SZN-8141 as a potential multi-indication therapy for retinal diseases, with plans to evaluate its activity in both DME and wet AMD. Surrozen is a biotechnology company developing Wnt-based therapeutics for sight-threatening ophthalmic conditions. Its approach combines selective Wnt pathway activation with other disease-relevant pathways through multifunctional biologics designed to address underlying mechanisms of ocular disease. Currently, SRZN is trading at $22.31, down 1.98%. For comments and feedback contact: [email protected] Business News September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.